Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors

BOCA RATON, Fla., Feb. 8, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (Pink Sheets: SCLZ) announced today the engagement of Marcum LLP to audit its financial statements as of December 31, 2009 and 2010 and for the years then ended.  Ranked 15th among the "Top 25 Firms" by Inside Public Accounting, Marcum offers the resources of more than 1,100 professionals, including more than 150 partners, in 23 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman, China and Hong Kong.

Mark Weinreb, Stem Cell Assurance's CEO, stated, "We are very pleased to announce the engagement of Marcum as our auditors.  The auditing of our financial statements by such a prestigious accounting firm will move us closer to becoming an established company in the stem cell arena."

About Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications. The Company intends to offer processing and storage of adipose-derived adult stem cells for use in certain aesthetic cosmetic treatments. The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which offers and sells facial creams and products.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

SOURCE Stem Cell Assurance, Inc.